December 25, 2025 07:24 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Tarique Rahman returns to Bangladesh after 17 years | Shocking killing inside AMU campus: teacher shot dead during evening walk | Horror on Karnataka highway: sleeper bus bursts into flames after truck crash, 9 killed | PM Modi attends Christmas service at Delhi church, sends message of love and compassion | Delhi erupts over lynching of Hindu man in Bangladesh; protest outside High Commission | Targeted killing sparks global outrage: American lawmakers condemn mob lynching of Hindu man in Bangladesh | Assam on a ‘powder keg’: Himanta Biswa Sarma flags demographic shift, Chicken’s Neck fears | Bangladesh on edge: Student leader shot as pre-poll violence deepens after Hadi killing | Historic deal sealed: India, New Zealand sign landmark Free Trade Agreement in record time | Supreme court snubs urgent plea to stop PMO’s chadar offering at Ajmer Sharif

Singapore to begin human clinical trials on potential coronavirus treatment - Reports

| @indiablooms | Jun 10, 2020, at 04:26 pm

Moscow/Sputnik/UNI: Singapore will begin human clinical trials on a domestically developed treatment candidate for the coronavirus next week, media reported Wednesday.

According to the Singapore news outlet, The Strait Times, biotechnology company Tychan will administer the experimental treatment to 23 healthy individuals and monitor the results over six weeks.

The medication in question is the TY027, which was developed to specifically target Sars-Cov-2, the virus that causes COVID-19, the newspaper reported.

The medication is being studied for qualities of slowing the spread of the virus, speeding up recovery and even protecting against the infection, according to The Strait Times.

Tychan is one of the dozens of companies around the world racing to develop treatments and vaccines against the coronavirus, which has so far infected more than 7.3 million people and killed over 410,000. 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.